Global (North America, Europe, Asia-Pacific, South America, Middle East and Africa) Multiple Myeloma Drugs Market 2018, Forecast to 2023

Publisher Name :
Date: 11-Jan-2019
No. of pages: 135

Multiple myeloma is a cancer that forms in a type of white blood cell that is called a plasma cell. Plasma cells help to fight infections by making antibodies. Multiple myeloma causes cancer cells to accumulate in the bone marrow, where they crowd out healthy blood cells. Rather than produce helpful antibodies, the cancer cells produce abnormal proteins that can cause complications. For people with multiple myeloma who require treatment, a number of treatments are available to help control the disease.

Scope of the Report:

This report focuses on the Multiple Myeloma Drugs in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.

Cancer cells have higher levels of proteasome activity are more sensitive to the proapoptotic effects of proteasome inhibition than normal cells, which makes the proteasome a therapeutic target in multiple myeloma. Proteasome inhibitor treatment is preferred after there is a treatment failure with the conventional approach.

The worldwide market for Multiple Myeloma Drugs is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to a new GIR (Global Info Research) study.

Market Segment by Manufacturers, this report covers

- Amgen

- Johnson & Johnson

- Celgene

- Takeda Pharmaceutical

- Novartis

- Daiichi Sankyo

- Merck

- AB Science

- Teva

- PharmaMar

Market Segment by Regions, regional analysis covers

- North America (United States, Canada and Mexico)

- Europe (Germany, France, UK, Russia and Italy)

- Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

- South America (Brazil, Argentina, Colombia etc.)

- Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Market Segment by Type, covers

- Immunomodulatory drugs (IMiDs)

- Proteasome inhibitors

- Chemotherapy

- Histone deacetylase inhibitor (HDAC inhibitor)

- Steroids (corticosteroids)

Market Segment by Applications, can be divided into

- Men

- Women

There are 15 Chapters to deeply display the global Multiple Myeloma Drugs market.

Chapter 1, to describe Multiple Myeloma Drugs Introduction, product scope, market overview, market opportunities, market risk, market driving force;

Chapter 2, to analyze the top manufacturers of Multiple Myeloma Drugs, with sales, revenue, and price of Multiple Myeloma Drugs, in 2016 and 2017;

Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;

Chapter 4, to show the global market by regions, with sales, revenue and market share of Multiple Myeloma Drugs, for each region, from 2013 to 2018;

Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;

Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;

Chapter 12, Multiple Myeloma Drugs market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;

Chapter 13, 14 and 15, to describe Multiple Myeloma Drugs sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source

Global (North America, Europe, Asia-Pacific, South America, Middle East and Africa) Multiple Myeloma Drugs Market 2018, Forecast to 2023

Table of Contents

1 Market Overview
1.1 Multiple Myeloma Drugs Introduction
1.2 Market Analysis by Type
1.2.1 Immunomodulatory drugs (IMiDs)
1.2.2 Proteasome inhibitors
1.2.3 Chemotherapy
1.2.4 Histone deacetylase inhibitor (HDAC inhibitor)
1.2.5 Steroids (corticosteroids)
1.3 Market Analysis by Applications
1.3.1 Men
1.3.2 Women
1.4 Market Analysis by Regions
1.4.1 North America (United States, Canada and Mexico)
1.4.1.1 United States Market States and Outlook (2013-2023)
1.4.1.2 Canada Market States and Outlook (2013-2023)
1.4.1.3 Mexico Market States and Outlook (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy)
1.4.2.1 Germany Market States and Outlook (2013-2023)
1.4.2.2 France Market States and Outlook (2013-2023)
1.4.2.3 UK Market States and Outlook (2013-2023)
1.4.2.4 Russia Market States and Outlook (2013-2023)
1.4.2.5 Italy Market States and Outlook (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
1.4.3.1 China Market States and Outlook (2013-2023)
1.4.3.2 Japan Market States and Outlook (2013-2023)
1.4.3.3 Korea Market States and Outlook (2013-2023)
1.4.3.4 India Market States and Outlook (2013-2023)
1.4.3.5 Southeast Asia Market States and Outlook (2013-2023)
1.4.4 South America, Middle East and Africa
1.4.4.1 Brazil Market States and Outlook (2013-2023)
1.4.4.2 Egypt Market States and Outlook (2013-2023)
1.4.4.3 Saudi Arabia Market States and Outlook (2013-2023)
1.4.4.4 South Africa Market States and Outlook (2013-2023)
1.4.4.5 Nigeria Market States and Outlook (2013-2023)
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force
2 Manufacturers Profiles
2.1 Amgen
2.1.1 Business Overview
2.1.1.1 Amgen Description
2.1.1.2 Amgen Headquarter, Main Business and Finance Overview
2.1.2 Amgen Multiple Myeloma Drugs Product Introduction
2.1.2.1 Multiple Myeloma Drugs Production Bases, Sales Regions and Major Competitors
2.1.2.2 Multiple Myeloma Drugs Product Information
2.1.3 Amgen Multiple Myeloma Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.1.3.1 Amgen Multiple Myeloma Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.1.3.2 Global Amgen Multiple Myeloma Drugs Market Share in 2017
2.2 Johnson & Johnson
2.2.1 Business Overview
2.2.1.1 Johnson & Johnson Description
2.2.1.2 Johnson & Johnson Headquarter, Main Business and Finance Overview
2.2.2 Johnson & Johnson Multiple Myeloma Drugs Product Introduction
2.2.2.1 Multiple Myeloma Drugs Production Bases, Sales Regions and Major Competitors
2.2.2.2 Multiple Myeloma Drugs Product Information
2.2.3 Johnson & Johnson Multiple Myeloma Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.2.3.1 Johnson & Johnson Multiple Myeloma Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.2.3.2 Global Johnson & Johnson Multiple Myeloma Drugs Market Share in 2017
2.3 Celgene
2.3.1 Business Overview
2.3.1.1 Celgene Description
2.3.1.2 Celgene Headquarter, Main Business and Finance Overview
2.3.2 Celgene Multiple Myeloma Drugs Product Introduction
2.3.2.1 Multiple Myeloma Drugs Production Bases, Sales Regions and Major Competitors
2.3.2.2 Multiple Myeloma Drugs Product Information
2.3.3 Celgene Multiple Myeloma Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.3.3.1 Celgene Multiple Myeloma Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.3.3.2 Global Celgene Multiple Myeloma Drugs Market Share in 2017
2.4 Takeda Pharmaceutical
2.4.1 Business Overview
2.4.1.1 Takeda Pharmaceutical Description
2.4.1.2 Takeda Pharmaceutical Headquarter, Main Business and Finance Overview
2.4.2 Takeda Pharmaceutical Multiple Myeloma Drugs Product Introduction
2.4.2.1 Multiple Myeloma Drugs Production Bases, Sales Regions and Major Competitors
2.4.2.2 Multiple Myeloma Drugs Product Information
2.4.3 Takeda Pharmaceutical Multiple Myeloma Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.4.3.1 Takeda Pharmaceutical Multiple Myeloma Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.4.3.2 Global Takeda Pharmaceutical Multiple Myeloma Drugs Market Share in 2017
2.5 Novartis
2.5.1 Business Overview
2.5.1.1 Novartis Description
2.5.1.2 Novartis Headquarter, Main Business and Finance Overview
2.5.2 Novartis Multiple Myeloma Drugs Product Introduction
2.5.2.1 Multiple Myeloma Drugs Production Bases, Sales Regions and Major Competitors
2.5.2.2 Multiple Myeloma Drugs Product Information
2.5.3 Novartis Multiple Myeloma Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.5.3.1 Novartis Multiple Myeloma Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.5.3.2 Global Novartis Multiple Myeloma Drugs Market Share in 2017
2.6 Daiichi Sankyo
2.6.1 Business Overview
2.6.1.1 Daiichi Sankyo Description
2.6.1.2 Daiichi Sankyo Headquarter, Main Business and Finance Overview
2.6.2 Daiichi Sankyo Multiple Myeloma Drugs Product Introduction
2.6.2.1 Multiple Myeloma Drugs Production Bases, Sales Regions and Major Competitors
2.6.2.2 Multiple Myeloma Drugs Product Information
2.6.3 Daiichi Sankyo Multiple Myeloma Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.6.3.1 Daiichi Sankyo Multiple Myeloma Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.6.3.2 Global Daiichi Sankyo Multiple Myeloma Drugs Market Share in 2017
2.7 Merck
2.7.1 Business Overview
2.7.1.1 Merck Description
2.7.1.2 Merck Headquarter, Main Business and Finance Overview
2.7.2 Merck Multiple Myeloma Drugs Product Introduction
2.7.2.1 Multiple Myeloma Drugs Production Bases, Sales Regions and Major Competitors
2.7.2.2 Multiple Myeloma Drugs Product Information
2.7.3 Merck Multiple Myeloma Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.7.3.1 Merck Multiple Myeloma Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.7.3.2 Global Merck Multiple Myeloma Drugs Market Share in 2017
2.8 AB Science
2.8.1 Business Overview
2.8.1.1 AB Science Description
2.8.1.2 AB Science Headquarter, Main Business and Finance Overview
2.8.2 AB Science Multiple Myeloma Drugs Product Introduction
2.8.2.1 Multiple Myeloma Drugs Production Bases, Sales Regions and Major Competitors
2.8.2.2 Multiple Myeloma Drugs Product Information
2.8.3 AB Science Multiple Myeloma Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.8.3.1 AB Science Multiple Myeloma Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.8.3.2 Global AB Science Multiple Myeloma Drugs Market Share in 2017
2.9 Teva
2.9.1 Business Overview
2.9.1.1 Teva Description
2.9.1.2 Teva Headquarter, Main Business and Finance Overview
2.9.2 Teva Multiple Myeloma Drugs Product Introduction
2.9.2.1 Multiple Myeloma Drugs Production Bases, Sales Regions and Major Competitors
2.9.2.2 Multiple Myeloma Drugs Product Information
2.9.3 Teva Multiple Myeloma Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.9.3.1 Teva Multiple Myeloma Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.9.3.2 Global Teva Multiple Myeloma Drugs Market Share in 2017
2.10 PharmaMar
2.10.1 Business Overview
2.10.1.1 PharmaMar Description
2.10.1.2 PharmaMar Headquarter, Main Business and Finance Overview
2.10.2 PharmaMar Multiple Myeloma Drugs Product Introduction
2.10.2.1 Multiple Myeloma Drugs Production Bases, Sales Regions and Major Competitors
2.10.2.2 Multiple Myeloma Drugs Product Information
2.10.3 PharmaMar Multiple Myeloma Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.10.3.1 PharmaMar Multiple Myeloma Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.10.3.2 Global PharmaMar Multiple Myeloma Drugs Market Share in 2017
3 Global Multiple Myeloma Drugs Market Competition, by Manufacturer
3.1 Global Multiple Myeloma Drugs Sales and Market Share by Manufacturer (2016-2017)
3.2 Global Multiple Myeloma Drugs Revenue and Market Share by Manufacturer (2016-2017)
3.3 Global Multiple Myeloma Drugs Price by Manufacturer (2016-2017)
3.4 Market Concentration Rate
3.4.1 Top 3 Multiple Myeloma Drugs Manufacturer Market Share in 2017
3.4.2 Top 5 Multiple Myeloma Drugs Manufacturer Market Share in 2017
3.5 Market Competition Trend
4 Global Multiple Myeloma Drugs Market Analysis by Regions
4.1 Global Multiple Myeloma Drugs Sales, Revenue and Market Share by Regions
4.1.1 Global Multiple Myeloma Drugs Sales by Regions (2013-2018)
4.1.2 Global Multiple Myeloma Drugs Revenue by Regions (2013-2018)
4.2 North America Multiple Myeloma Drugs Sales, Revenue and Growth Rate (2013-2018)
4.3 Europe Multiple Myeloma Drugs Sales, Revenue and Growth Rate (2013-2018)
4.4 Asia-Pacific Multiple Myeloma Drugs Sales, Revenue and Growth Rate (2013-2018)
4.5 South America Multiple Myeloma Drugs Sales, Revenue and Growth Rate (2013-2018)
4.6 Middle East and Africa Multiple Myeloma Drugs Sales, Revenue and Growth Rate (2013-2018)
5 North America Multiple Myeloma Drugs by Countries, Type, Application and Manufacturers
5.1 North America Multiple Myeloma Drugs Sales, Revenue and Market Share by Countries
5.1.1 North America Multiple Myeloma Drugs Sales by Countries (2013-2018)
5.1.2 North America Multiple Myeloma Drugs Revenue by Countries (2013-2018)
5.1.3 United States Multiple Myeloma Drugs Sales and Growth Rate (2013-2018)
5.1.4 Canada Multiple Myeloma Drugs Sales and Growth Rate (2013-2018)
5.1.5 Mexico Multiple Myeloma Drugs Sales and Growth Rate (2013-2018)
5.2 North America Multiple Myeloma Drugs Sales and Revenue (Value) by Manufacturers (2016-2017)
5.2.1 North America Multiple Myeloma Drugs Sales by Manufacturers (2016-2017)
5.2.2 North America Multiple Myeloma Drugs Revenue by Manufacturers (2016-2017)
5.3 North America Multiple Myeloma Drugs Sales, Revenue and Market Share by Type (2013-2018)
5.3.1 North America Multiple Myeloma Drugs Sales and Sales Share by Type (2013-2018)
5.3.2 North America Multiple Myeloma Drugs Revenue and Revenue Share by Type (2013-2018)
5.4 North America Multiple Myeloma Drugs Sales, Revenue and Market Share by Application (2013-2018)
5.4.1 North America Multiple Myeloma Drugs Sales and Sales Share by Application (2013-2018)
5.4.2 North America Multiple Myeloma Drugs Revenue and Revenue Share by Application (2013-2018)
6 Europe Multiple Myeloma Drugs by Countries, Type, Application and Manufacturers
6.1 Europe Multiple Myeloma Drugs Sales, Revenue and Market Share by Countries
6.1.1 Europe Multiple Myeloma Drugs Sales by Countries (2013-2018)
6.1.2 Europe Multiple Myeloma Drugs Revenue by Countries (2013-2018)
6.1.3 Germany Multiple Myeloma Drugs Sales and Growth Rate (2013-2018)
6.1.4 UK Multiple Myeloma Drugs Sales and Growth Rate (2013-2018)
6.1.5 France Multiple Myeloma Drugs Sales and Growth Rate (2013-2018)
6.1.6 Russia Multiple Myeloma Drugs Sales and Growth Rate (2013-2018)
6.1.7 Italy Multiple Myeloma Drugs Sales and Growth Rate (2013-2018)
6.2 Europe Multiple Myeloma Drugs Sales and Revenue (Value) by Manufacturers (2016-2017)
6.2.1 Europe Multiple Myeloma Drugs Sales by Manufacturers (2016-2017)
6.2.2 Europe Multiple Myeloma Drugs Revenue by Manufacturers (2016-2017)
6.3 Europe Multiple Myeloma Drugs Sales, Revenue and Market Share by Type (2013-2018)
6.3.1 Europe Multiple Myeloma Drugs Sales and Sales Share by Type (2013-2018)
6.3.2 Europe Multiple Myeloma Drugs Revenue and Revenue Share by Type (2013-2018)
6.4 Europe Multiple Myeloma Drugs Sales, Revenue and Market Share by Application (2013-2018)
6.4.1 Europe Multiple Myeloma Drugs Sales and Sales Share by Application (2013-2018)
6.4.2 Europe Multiple Myeloma Drugs Revenue and Revenue Share by Application (2013-2018)
7 Asia-Pacific Multiple Myeloma Drugs by Countries, Type, Application and Manufacturers
7.1 Asia-Pacific Multiple Myeloma Drugs Sales, Revenue and Market Share by Countries
7.1.1 Asia-Pacific Multiple Myeloma Drugs Sales by Countries (2013-2018)
7.1.2 Asia-Pacific Multiple Myeloma Drugs Revenue by Countries (2013-2018)
7.1.3 China Multiple Myeloma Drugs Sales and Growth Rate (2013-2018)
7.1.4 Japan Multiple Myeloma Drugs Sales and Growth Rate (2013-2018)
7.1.5 Korea Multiple Myeloma Drugs Sales and Growth Rate (2013-2018)
7.1.6 India Multiple Myeloma Drugs Sales and Growth Rate (2013-2018)
7.1.7 Southeast Asia Multiple Myeloma Drugs Sales and Growth Rate (2013-2018)
7.2 Asia-Pacific Multiple Myeloma Drugs Sales and Revenue (Value) by Manufacturers (2016-2017)
7.2.1 Asia-Pacific Multiple Myeloma Drugs Sales by Manufacturers (2016-2017)
7.2.2 Asia-Pacific Multiple Myeloma Drugs Revenue by Manufacturers (2016-2017)
7.3 Asia-Pacific Multiple Myeloma Drugs Sales, Revenue and Market Share by Type (2013-2018)
7.3.1 Asia-Pacific Multiple Myeloma Drugs Sales and Sales Share by Type (2013-2018)
7.3.2 Asia-Pacific Multiple Myeloma Drugs Revenue and Revenue Share by Type (2013-2018)
7.4 Asia-Pacific Multiple Myeloma Drugs Sales, Revenue and Market Share by Application (2013-2018)
7.4.1 Asia-Pacific Multiple Myeloma Drugs Sales and Sales Share by Application (2013-2018)
7.4.2 Asia-Pacific Multiple Myeloma Drugs Revenue and Revenue Share by Application (2013-2018)
8 South America Multiple Myeloma Drugs by Countries, Type, Application and Manufacturers
8.1 South America Multiple Myeloma Drugs Sales, Revenue and Market Share by Countries
8.1.1 South America Multiple Myeloma Drugs Sales by Countries (2013-2018)
8.1.2 South America Multiple Myeloma Drugs Revenue by Countries (2013-2018)
8.1.3 Brazil Multiple Myeloma Drugs Sales and Growth Rate (2013-2018)
8.1.4 Argentina Multiple Myeloma Drugs Sales and Growth Rate (2013-2018)
8.1.5 Colombia Multiple Myeloma Drugs Sales and Growth Rate (2013-2018)
8.2 South America Multiple Myeloma Drugs Sales and Revenue (Value) by Manufacturers (2016-2017)
8.2.1 South America Multiple Myeloma Drugs Sales by Manufacturers (2016-2017)
8.2.2 South America Multiple Myeloma Drugs Revenue by Manufacturers (2016-2017)
8.3 South America Multiple Myeloma Drugs Sales, Revenue and Market Share by Type (2013-2018)
8.3.1 South America Multiple Myeloma Drugs Sales and Sales Share by Type (2013-2018)
8.3.2 South America Multiple Myeloma Drugs Revenue and Revenue Share by Type (2013-2018)
8.4 South America Multiple Myeloma Drugs Sales, Revenue and Market Share by Application (2013-2018)
8.4.1 South America Multiple Myeloma Drugs Sales and Sales Share by Application (2013-2018)
8.4.2 South America Multiple Myeloma Drugs Revenue and Revenue Share by Application (2013-2018)
9 Middle East and Africa Multiple Myeloma Drugs by Countries, Type, Application and Manufacturers
9.1 Middle East and Africa Multiple Myeloma Drugs Sales, Revenue and Market Share by Countries
9.1.1 Middle East and Africa Multiple Myeloma Drugs Sales by Countries (2013-2018)
9.1.2 Middle East and Africa Multiple Myeloma Drugs Revenue by Countries (2013-2018)
9.1.3 Saudi Arabia Multiple Myeloma Drugs Sales and Growth Rate (2013-2018)
9.1.4 UAE Multiple Myeloma Drugs Sales and Growth Rate (2013-2018)
9.1.5 Egypt Multiple Myeloma Drugs Sales and Growth Rate (2013-2018)
9.1.6 Nigeria Multiple Myeloma Drugs Sales and Growth Rate (2013-2018)
9.1.7 South Africa Multiple Myeloma Drugs Sales and Growth Rate (2013-2018)
9.2 Middle East and Africa Multiple Myeloma Drugs Sales and Revenue (Value) by Manufacturers (2016-2017)
9.2.1 Middle East and Africa Multiple Myeloma Drugs Sales by Manufacturers (2016-2017)
9.2.2 Middle East and Africa Multiple Myeloma Drugs Revenue by Manufacturers (2016-2017)
9.3 Middle East and Africa Multiple Myeloma Drugs Sales, Revenue and Market Share by Type (2013-2018)
9.3.1 Middle East and Africa Multiple Myeloma Drugs Sales and Sales Share by Type (2013-2018)
9.3.1 Middle East and Africa Multiple Myeloma Drugs Revenue and Revenue Share by Type (2013-2018)
9.4 Middle East and Africa Multiple Myeloma Drugs Sales, Revenue and Market Share by Application (2013-2018)
9.4.1 Middle East and Africa Multiple Myeloma Drugs Sales and Sales Share by Application (2013-2018)
9.4.2 Middle East and Africa Multiple Myeloma Drugs Revenue and Revenue Share by Application (2013-2018)
10 Global Multiple Myeloma Drugs Market Segment by Type
10.1 Global Multiple Myeloma Drugs Sales, Revenue and Market Share by Type (2013-2018)
10.1.1 Global Multiple Myeloma Drugs Sales and Market Share by Type (2013-2018)
10.1.2 Global Multiple Myeloma Drugs Revenue and Market Share by Type (2013-2018)
10.2 Immunomodulatory drugs (IMiDs) Sales Growth and Price
10.2.1 Global Immunomodulatory drugs (IMiDs) Sales Growth (2013-2018)
10.2.2 Global Immunomodulatory drugs (IMiDs) Price (2013-2018)
10.3 Proteasome inhibitors Sales Growth and Price
10.3.1 Global Proteasome inhibitors Sales Growth (2013-2018)
10.3.2 Global Proteasome inhibitors Price (2013-2018)
10.4 Chemotherapy Sales Growth and Price
10.4.1 Global Chemotherapy Sales Growth (2013-2018)
10.4.2 Global Chemotherapy Price (2013-2018)
10.5 Histone deacetylase inhibitor (HDAC inhibitor) Sales Growth and Price
10.5.1 Global Histone deacetylase inhibitor (HDAC inhibitor) Sales Growth (2013-2018)
10.5.2 Global Histone deacetylase inhibitor (HDAC inhibitor) Price (2013-2018)
10.6 Steroids (corticosteroids) Sales Growth and Price
10.6.1 Global Steroids (corticosteroids) Sales Growth (2013-2018)
10.6.2 Global Steroids (corticosteroids) Price (2013-2018)
11 Global Multiple Myeloma Drugs Market Segment by Application
11.1 Global Multiple Myeloma Drugs Sales Market Share by Application (2013-2018)
11.2 Men Sales Growth (2013-2018)
11.3 Women Sales Growth (2013-2018)
12 Multiple Myeloma Drugs Market Forecast (2018-2023)
12.1 Global Multiple Myeloma Drugs Sales, Revenue and Growth Rate (2018-2023)
12.2 Multiple Myeloma Drugs Market Forecast by Regions (2018-2023)
12.2.1 North America Multiple Myeloma Drugs Market Forecast (2018-2023)
12.2.2 Europe Multiple Myeloma Drugs Market Forecast (2018-2023)
12.2.3 Asia-Pacific Multiple Myeloma Drugs Market Forecast (2018-2023)
12.2.4 South America Multiple Myeloma Drugs Market Forecast (2018-2023)
12.2.5 Middle East and Africa Multiple Myeloma Drugs Market Forecast (2018-2023)
12.3 Multiple Myeloma Drugs Market Forecast by Type (2018-2023)
12.3.1 Global Multiple Myeloma Drugs Sales Forecast by Type (2018-2023)
12.3.2 Global Multiple Myeloma Drugs Market Share Forecast by Type (2018-2023)
12.4 Multiple Myeloma Drugs Market Forecast by Application (2018-2023)
12.4.1 Global Multiple Myeloma Drugs Sales Forecast by Application (2018-2023)
12.4.2 Global Multiple Myeloma Drugs Market Share Forecast by Application (2018-2023)
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.1.3 Marketing Channel Future Trend
13.2 Distributors, Traders and Dealers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Data Source

List of Tables and Figures

Figure Multiple Myeloma Drugs Picture
Table Product Specifications of Multiple Myeloma Drugs
Figure Global Multiple Myeloma Drugs CAGR (%), Y-o-Y Growth (&) and Market Size, 2013-2023 (USD Million)
Figure Global Multiple Myeloma Drugs CAGR (%), Y-o-Y Growth (&) and Market Size, 2013-2023 (Sales)
Figure Global Sales Market Share of Multiple Myeloma Drugs by Types in 2017
Figure Immunomodulatory drugs (IMiDs) Picture
Table Major Manufacturers of Immunomodulatory drugs (IMiDs)
Figure Proteasome inhibitors Picture
Table Major Manufacturers of Proteasome inhibitors
Figure Chemotherapy Picture
Table Major Manufacturers of Chemotherapy
Figure Histone deacetylase inhibitor (HDAC inhibitor) Picture
Table Major Manufacturers of Histone deacetylase inhibitor (HDAC inhibitor)
Figure Steroids (corticosteroids) Picture
Table Major Manufacturers of Steroids (corticosteroids)
Figure Multiple Myeloma Drugs Sales Market Share by Applications in 2017
Figure Men Picture
Figure Women Picture
Figure United States Multiple Myeloma Drugs Revenue (Value) and Growth Rate (2013-2023)
Figure Canada Multiple Myeloma Drugs Revenue (Value) and Growth Rate (2013-2023)
Figure Mexico Multiple Myeloma Drugs Revenue (Value) and Growth Rate (2013-2023)
Figure Germany Multiple Myeloma Drugs Revenue (Value) and Growth Rate (2013-2023)
Figure France Multiple Myeloma Drugs Revenue (Value) and Growth Rate (2013-2023)
Figure UK Multiple Myeloma Drugs Revenue (Value) and Growth Rate (2013-2023)
Figure Russia Multiple Myeloma Drugs Revenue (Value) and Growth Rate (2013-2023)
Figure Italy Multiple Myeloma Drugs Revenue (Value) and Growth Rate (2013-2023)
Figure China Multiple Myeloma Drugs Revenue (Value) and Growth Rate (2013-2023)
Figure Japan Multiple Myeloma Drugs Revenue (Value) and Growth Rate (2013-2023)
Figure Korea Multiple Myeloma Drugs Revenue (Value) and Growth Rate (2013-2023)
Figure India Multiple Myeloma Drugs Revenue (Value) and Growth Rate (2013-2023)
Figure Southeast Asia Multiple Myeloma Drugs Revenue (Value) and Growth Rate (2013-2023)
Figure Brazil Multiple Myeloma Drugs Revenue (Value) and Growth Rate (2013-2023)
Figure Egypt Multiple Myeloma Drugs Revenue (Value) and Growth Rate (2013-2023)
Figure Saudi Arabia Multiple Myeloma Drugs Revenue (Value) and Growth Rate (2013-2023)
Figure South Africa Multiple Myeloma Drugs Revenue (Value) and Growth Rate (2013-2023)
Figure Nigeria Multiple Myeloma Drugs Revenue (Value) and Growth Rate (2013-2023)
Table Amgen Headquarter, Established, Main Business and Finance Overview (2017)
Table Amgen Multiple Myeloma Drugs Production Bases, Sales Regions and Major Competitors
Table Amgen Multiple Myeloma Drugs Product
Table Amgen Multiple Myeloma Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Figure Global Amgen Multiple Myeloma Drugs Sales Market Share in 2017
Figure Global Amgen Multiple Myeloma Drugs Revenue Market Share in 2017
Table Johnson & Johnson Headquarter, Established, Main Business and Finance Overview (2017)
Table Johnson & Johnson Multiple Myeloma Drugs Production Bases, Sales Regions and Major Competitors
Table Johnson & Johnson Multiple Myeloma Drugs Product
Table Johnson & Johnson Multiple Myeloma Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Figure Global Johnson & Johnson Multiple Myeloma Drugs Sales Market Share in 2017
Figure Global Johnson & Johnson Multiple Myeloma Drugs Revenue Market Share in 2017
Table Celgene Headquarter, Established, Main Business and Finance Overview (2017)
Table Celgene Multiple Myeloma Drugs Production Bases, Sales Regions and Major Competitors
Table Celgene Multiple Myeloma Drugs Product
Table Celgene Multiple Myeloma Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Figure Global Celgene Multiple Myeloma Drugs Sales Market Share in 2017
Figure Global Celgene Multiple Myeloma Drugs Revenue Market Share in 2017
Table Takeda Pharmaceutical Headquarter, Established, Main Business and Finance Overview (2017)
Table Takeda Pharmaceutical Multiple Myeloma Drugs Production Bases, Sales Regions and Major Competitors
Table Takeda Pharmaceutical Multiple Myeloma Drugs Product
Table Takeda Pharmaceutical Multiple Myeloma Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Figure Global Takeda Pharmaceutical Multiple Myeloma Drugs Sales Market Share in 2017
Figure Global Takeda Pharmaceutical Multiple Myeloma Drugs Revenue Market Share in 2017
Table Novartis Headquarter, Established, Main Business and Finance Overview (2017)
Table Novartis Multiple Myeloma Drugs Production Bases, Sales Regions and Major Competitors
Table Novartis Multiple Myeloma Drugs Product
Table Novartis Multiple Myeloma Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Figure Global Novartis Multiple Myeloma Drugs Sales Market Share in 2017
Figure Global Novartis Multiple Myeloma Drugs Revenue Market Share in 2017
Table Daiichi Sankyo Headquarter, Established, Main Business and Finance Overview (2017)
Table Daiichi Sankyo Multiple Myeloma Drugs Production Bases, Sales Regions and Major Competitors
Table Daiichi Sankyo Multiple Myeloma Drugs Product
Table Daiichi Sankyo Multiple Myeloma Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Figure Global Daiichi Sankyo Multiple Myeloma Drugs Sales Market Share in 2017
Figure Global Daiichi Sankyo Multiple Myeloma Drugs Revenue Market Share in 2017
Table Merck Headquarter, Established, Main Business and Finance Overview (2017)
Table Merck Multiple Myeloma Drugs Production Bases, Sales Regions and Major Competitors
Table Merck Multiple Myeloma Drugs Product
Table Merck Multiple Myeloma Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Figure Global Merck Multiple Myeloma Drugs Sales Market Share in 2017
Figure Global Merck Multiple Myeloma Drugs Revenue Market Share in 2017
Table AB Science Headquarter, Established, Main Business and Finance Overview (2017)
Table AB Science Multiple Myeloma Drugs Production Bases, Sales Regions and Major Competitors
Table AB Science Multiple Myeloma Drugs Product
Table AB Science Multiple Myeloma Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Figure Global AB Science Multiple Myeloma Drugs Sales Market Share in 2017
Figure Global AB Science Multiple Myeloma Drugs Revenue Market Share in 2017
Table Teva Headquarter, Established, Main Business and Finance Overview (2017)
Table Teva Multiple Myeloma Drugs Production Bases, Sales Regions and Major Competitors
Table Teva Multiple Myeloma Drugs Product
Table Teva Multiple Myeloma Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Figure Global Teva Multiple Myeloma Drugs Sales Market Share in 2017
Figure Global Teva Multiple Myeloma Drugs Revenue Market Share in 2017
Table PharmaMar Headquarter, Established, Main Business and Finance Overview (2017)
Table PharmaMar Multiple Myeloma Drugs Production Bases, Sales Regions and Major Competitors
Table PharmaMar Multiple Myeloma Drugs Product
Table PharmaMar Multiple Myeloma Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Figure Global PharmaMar Multiple Myeloma Drugs Sales Market Share in 2017
Figure Global PharmaMar Multiple Myeloma Drugs Revenue Market Share in 2017
Table Global Multiple Myeloma Drugs Sales by Manufacturer (2016-2017)
Figure Global Multiple Myeloma Drugs Sales Market Share by Manufacturer in 2016
Figure Global Multiple Myeloma Drugs Sales Market Share by Manufacturer in 2017
Table Global Multiple Myeloma Drugs Revenue by Manufacturer (2016-2017)
Figure Global Multiple Myeloma Drugs Revenue Market Share by Manufacturer in 2016
Figure Global Multiple Myeloma Drugs Revenue Market Share by Manufacturer in 2017
Table Global Multiple Myeloma Drugs Price by Manufacturer (2016-2017)
Figure Top 3 Multiple Myeloma Drugs Manufacturer (Revenue) Market Share in 2017
Figure Top 6 Multiple Myeloma Drugs Manufacturer (Revenue) Market Share in 2017
Figure Global Multiple Myeloma Drugs Sales and Growth Rate (2013-2018)
Figure Global Multiple Myeloma Drugs Revenue and Growth Rate (2013-2018)
Table Global Multiple Myeloma Drugs Sales by Regions (2013-2018)
Table Global Multiple Myeloma Drugs Sales Market Share by Regions (2013-2018)
Table Global Multiple Myeloma Drugs Revenue by Regions (2013-2018)
Figure Global Multiple Myeloma Drugs Revenue Market Share by Regions in 2013
Figure Global Multiple Myeloma Drugs Revenue Market Share by Regions in 2017
Figure North America Multiple Myeloma Drugs Sales and Growth Rate (2013-2018)
Figure North America Multiple Myeloma Drugs Revenue and Growth Rate (2013-2018)
Figure Europe Multiple Myeloma Drugs Sales and Growth Rate (2013-2018)
Figure Europe Multiple Myeloma Drugs Revenue and Growth Rate (2013-2018)
Figure Asia-Pacific Multiple Myeloma Drugs Sales and Growth Rate (2013-2018)
Figure Asia-Pacific Multiple Myeloma Drugs Revenue and Growth Rate (2013-2018)
Figure South America Multiple Myeloma Drugs Sales and Growth Rate (2013-2018)
Figure South America Multiple Myeloma Drugs Revenue and Growth Rate (2013-2018)
Figure Middle East and Africa Multiple Myeloma Drugs Sales and Growth Rate (2013-2018)
Figure Middle East and Africa Multiple Myeloma Drugs Revenue and Growth Rate (2013-2018)
Figure North America Multiple Myeloma Drugs Revenue and Growth Rate (2013-2018)
Table North America Multiple Myeloma Drugs Sales by Countries (2013-2018)
Table North America Multiple Myeloma Drugs Sales Market Share by Countries (2013-2018)
Figure North America Multiple Myeloma Drugs Sales Market Share by Countries in 2013
Figure North America Multiple Myeloma Drugs Sales Market Share by Countries in 2017
Table North America Multiple Myeloma Drugs Revenue by Countries (2013-2018)
Table North America Multiple Myeloma Drugs Revenue Market Share by Countries (2013-2018)
Figure North America Multiple Myeloma Drugs Revenue Market Share by Countries in 2013
Figure North America Multiple Myeloma Drugs Revenue Market Share by Countries in 2017
Figure United States Multiple Myeloma Drugs Sales and Growth Rate (2013-2018)
Figure Canada Multiple Myeloma Drugs Sales and Growth Rate (2013-2018)
Figure Mexico Multiple Myeloma Drugs Sales and Growth Rate (2013-2018)
Table North America Multiple Myeloma Drugs Sales by Manufacturer (2016-2017)
Figure North America Multiple Myeloma Drugs Sales Market Share by Manufacturer in 2016
Figure North America Multiple Myeloma Drugs Sales Market Share by Manufacturer in 2017
Table North America Multiple Myeloma Drugs Revenue by Manufacturer (2016-2017)
Figure North America Multiple Myeloma Drugs Revenue Market Share by Manufacturer in 2016
Figure North America Multiple Myeloma Drugs Revenue Market Share by Manufacturer in 2017
Table North America Multiple Myeloma Drugs Sales by Type (2013-2018)
Table North America Multiple Myeloma Drugs Sales Share by Type (2013-2018)
Table North America Multiple Myeloma Drugs Revenue by Type (2013-2018)
Table North America Multiple Myeloma Drugs Revenue Share by Type (2013-2018)
Table North America Multiple Myeloma Drugs Sale
  • Global Erbitux Market Insights, Forecast to 2025
    Published: 22-Apr-2019        Price: US 3900 Onwards        Pages: 115
    The global Erbitux market is valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. The objectives of this study are to define, segment, and project the size of the Erbitux market based on company, product type, end user and key regions. This report studies the global market size of Erbitux in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumptio......
  • Global Mitomycin C Market Data Survey Report 2013-2025
    Published: 20-Apr-2019        Price: US 1500 Onwards        Pages: 60
    Summary Mitomycin C is an antibiotic which acts as a double-stranded DNA alkylating agent. It covalently crosslinks DNA, inhibiting DNA synthesis and cell proliferation It acts by way of reductive activation either through low pH or NAD(P)H:quinone oxidoreductase (DT-diaphorase) or NADH cytochrome c reductase (Mao et al.; Cummings et al.). The global Mitomycin C market will reach xxx Million USD in 2019 with CAGR xx% 2019-2025. The main contents of the report including:......
  • Global Cancer Targeted Therapy Market Size, Status and Forecast 2019-2025
    Published: 19-Apr-2019        Price: US 3900 Onwards        Pages: 111
    In 2018, the global Cancer Targeted Therapy market size was million US$ and it is expected to reach million US$ by the end of 2025, with a CAGR of during 2019-2025. This report focuses on the global Cancer Targeted Therapy status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Cancer Targeted Therapy development in United States, Europe and China. The key players covered in this study - Advaxis ......
  • Global Carmustine Market Size, Status and Forecast 2019-2025
    Published: 18-Apr-2019        Price: US 3900 Onwards        Pages: 98
    In 2018, the global Carmustine market size was million US$ and it is expected to reach million US$ by the end of 2025, with a CAGR of during 2019-2025. This report focuses on the global Carmustine status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Carmustine development in United States, Europe and China. The key players covered in this study - J&K Scientific - Boc Sciences - LKT Labo......
  • Global Chemotheraphy Induced Nausea and Vomiting (CINV) Drugs Market Insights, Forecast to 2025
    Published: 18-Apr-2019        Price: US 3900 Onwards        Pages: 119
    The global Chemotheraphy Induced Nausea and Vomiting (CINV) Drugs market is valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. The objectives of this study are to define, segment, and project the size of the Chemotheraphy Induced Nausea and Vomiting (CINV) Drugs market based on company, product type, end user and key regions. This report studies the global market size of Chemotheraphy Induced Nausea and Vomiting (CIN......
  • Global Fluorouracil Market Insights, Forecast to 2025
    Published: 17-Apr-2019        Price: US 3900 Onwards        Pages: 113
    Global Fluorouracil market size will increase to Million US$ by 2025, from Million US$ in 2018, at a CAGR of during the forecast period. In this study, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Fluorouracil. This report researches the worldwide Fluorouracil market size (value, capacity, production and consumption) in key regions like United States, Europe, Asia Pacific (China, Japan) and other regions. ......
  • Global Megestrol Market Professional Survey 2019 by Manufacturers, Regions, Types and Applications, Forecast to 2024
    Published: 17-Apr-2019        Price: US 2600 Onwards        Pages: 149
    In this report, we analyze the Megestrol industry from two aspects. One part is about its production and the other part is about its consumption. In terms of its production, we analyze the production, revenue, gross margin of its main manufacturers and the unit price that they offer in different regions from 2014 to 2019. In terms of its consumption, we analyze the consumption volume, consumption value, sale price, import and export in different regions from 2014 to 2019. We also make a predicti......
  • Global Mitomycin C Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2024
    Published: 16-Apr-2019        Price: US 3480 Onwards        Pages: 120
    Mitomycin C market, Mitomycin C is an antibiotic which acts as a double-stranded DNA alkylating agent. It covalently crosslinks DNA, inhibiting DNA synthesis and cell proliferation It acts by way of reductive activation either through low pH or NAD(P)H:quinone oxidoreductase (DT-diaphorase) or NADH cytochrome c reductase (Mao et al.; Cummings et al.). Scope of the Report: In the last several years, Global market of Mitomycin C was experienced an upward trend rapidly, with a......
  • Global (United States, European Union and China) Cyclophosphamide Market Research Report 2019-2025
    Published: 16-Apr-2019        Price: US 3280 Onwards        Pages: 117
    In 2019, the market size of Cyclophosphamide is million US$ and it will reach million US$ in 2025, growing at a CAGR of from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period. In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Cyclophosphamide. This report studies the global market size of Cycl......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs